Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03077165 · ClinicalTrials.gov registry record · Phase 2
Dose-response Relationship Study of S42909 on Leg Ulcer Healing
A Phase 2 study of Venous Leg Ulcer, sponsored by Ilkos Therapeutic.
- Completed
- Registry status
- Phase 2
- Development phase
- 121
- Enrollment target
- 20
- Study locations
NCT03077165 is a Phase 2 study of Venous Leg Ulcer that has completed, run by Ilkos Therapeutic. The registered enrollment target is 121 participants, below the 242-participant average among 35 other Venous Leg Ulcer trials with a reported enrollment target (50% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT03077165, a Phase 2 study of Venous Leg Ulcer, has completed, sponsored by Ilkos Therapeutic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 121 participants
- Enrollment target
- 20
- Study locations
Study Summary
Dose-response relationship study of S42909 on leg ulcer healing after oral repeated administration in patients with active venous leg ulcer.
Conditions Studied
Interventions
- DRUG S42909 100 mg
- DRUG S42909 200 mg
- DRUG S42909 400 mg
- DRUG S42909 800 mg
- DRUG S42909 1200 mg
Study Locations (20)
California
- ILD Research Center - Carlsbad
- Center for Clinical Research Inc. - Carmichael
- Center for Clinical Research Inc. - Castro Valley
- Limb Preservation Platform, Inc. - Fresno
- Foot and Ankle Clinic - Los Angeles
- Stanford Hospitals and Clinics - Redwood City
- Center for Clinical Research Inc. - San Francisco
Other
- Centro Dr Bottini de flebologia y estetica - Ciudad Autonoma de Buenos Aire
- Hospital Italiano de La Plata - La Plata
- DIM Clinica Privada - Ramos Mejía
- Sanatorio Mapaci - Rosario
- Medizinische Universitaet Innsbruck Universitaetsklinik für Gefässchirurgie - Innsbruck
- VENEX Zentrum fuer minimal invasive Venentherapie - Vienna
Pennsylvania
- The Snyder Institute for Vascular Health and Research - Kittanning
- D&P Medical Group, LLC - Pittsburgh
- Serena Group Research Foundation - Pittsburgh
Florida
- University of Miami Hospital Wound Center - Miami
Idaho
- St. Luke's Intermountain Research Center - Boise
Illinois
- Podiatry 1st - Belleville
Nevada
- Advanced Foot & Ankle Center - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2017-09-12 |
| Est. Completion | 2020-01-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03077165
The ClinicalTrials.gov registry entry for NCT03077165 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 242-participant average among 35 other Venous Leg Ulcer trials with a reported enrollment target (50% lower). The listed sponsor is Ilkos Therapeutic, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Venous Leg Ulcer appearing as the primary indexed condition, and to 5 interventions - of which S42909 100 mg is the first listed.
NCT03077165 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Other, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03077165 about?
NCT03077165 is a clinical study titled "Dose-response Relationship Study of S42909 on Leg Ulcer Healing". Dose-response relationship study of S42909 on leg ulcer healing after oral repeated administration in patients with active venous leg ulcer.
What is the current status of trial NCT03077165?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 121 participants. The study started on 2017-09-12. Estimated completion is 2020-01-22.
What conditions does trial NCT03077165 study?
This clinical trial studies the following conditions: Venous Leg Ulcer.
What interventions are being tested in trial NCT03077165?
The interventions under investigation include: S42909 100 mg (DRUG), S42909 200 mg (DRUG), S42909 400 mg (DRUG), S42909 800 mg (DRUG), S42909 1200 mg (DRUG).
Who is sponsoring clinical trial NCT03077165?
This trial is sponsored by Ilkos Therapeutic, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03077165 being conducted?
This trial has 20 study locations across California, Florida, Idaho, Illinois, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Venous Leg Ulcer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dermacyte® Amniotic Wound Care Liquid for the Treatment of Non-Healing Venous Stasis Ulcers
RECRUITING · Phase 2
-
Efficacy of TR 987, Beta-1,3-1,6-D-glucan, in the Treatment of Chronic Venous Insufficiency Ulcers
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate the Safety and the Efficacy of EscharEx (EX-02 Formulation) in Debridement of Venous Leg Ulcers
COMPLETED · Phase 2
-
Study Assessing Complete Wound Healing by Comparing Surgenex® PelloGraft in Treating DFU and SanoGraft® in Treating VLU to SOC
RECRUITING · NA
-
Human Amniotic Membrane On Venous Leg Ulcers In an Elderly Population
RECRUITING · NA
-
A Clinical Investigation to Follow the Progress of Exuding Chronic Wounds Using Mepilex® Up as the Primary Dressing.
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.